NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

Harmony Campus
Memorial Hospital Central
Memorial Hospital North
University of Colorado Hospital

Study ID

Protocol Number: 18-2281

More information available at ClinicalTrials.gov: NCT03660826

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers